BridgeBio Pharma Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2020 | $-83.9M | $-88.4M | $4.5M | $10.2M |
| Jun 2020 | $-87.8M | $-88.2M | $346.0K | — |
| Sep 2020 | $-131.7M | $-132.2M | $549.0K | — |
| Mar 2021 | $-150.8M | $-152.7M | $2.0M | $33.6M |
| Jun 2021 | $-91.7M | $-94.0M | $2.3M | — |
| Sep 2021 | $-121.6M | $-128.0M | $6.5M | — |
| Mar 2022 | $-160.6M | $-161.5M | $859.0K | $24.1M |
| Jun 2022 | $-30.5M | $-32.9M | $2.4M | — |
| Sep 2022 | $-135.2M | $-135.9M | $759.0K | — |
| Mar 2023 | $-144.3M | $-144.3M | $12.0K | $21.9M |
| Jun 2023 | $-113.4M | $-113.8M | $428.0K | — |
| Sep 2023 | $-145.2M | $-145.7M | $431.0K | — |
| Mar 2024 | $-219.5M | $-220.2M | $695.0K | $17.1M |
| Jun 2024 | $74.7M | $74.6M | $54.0K | — |
| Sep 2024 | $-180.6M | $-180.7M | $137.0K | — |
| Mar 2025 | $-199.2M | $-199.2M | $0 | $25.9M |
| Jun 2025 | $-80.7M | $-81.3M | $594.0K | — |
| Sep 2025 | $-109.6M | $-110.0M | $470.0K | — |
| Mar 2026 | $-197.3M | $-197.3M | $69.0K | $33.2M |
| Jun 2026 | $-71.1M | $-71.5M | $443.0K | — |